This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NovoCure (NVCR) Moves 49.6% Higher: Will This Strength Last?
by Zacks Equity Research
NovoCure (NVCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
NovoCure (NVCR) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of -69.23% and -0.01%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for NovoCure (NVCR)
by Zacks Equity Research
NovoCure (NVCR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NovoCure (NVCR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
NovoCure (NVCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in NovoCure (NVCR) Stock?
by Zacks Equity Research
Investors need to pay close attention to NovoCure (NVCR) stock based on the movements in the options market lately.
Healthcare Stock Q3 Earnings Due on Oct 29: NVCR, CRL & More
by Zacks Equity Research
Coronavirus is going to affect the earnings results of healthcare players. While hospitals and health insurers might have suffered the COVID-19 impact, others providing virtual care and COVID-19-related services are likely to have gained from the same.
Kroger, Hyatt Hotels, ResMed, LHC Group and NovoCure highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Kroger, Hyatt Hotels, ResMed, LHC Group and NovoCure highlighted as Zacks Bull and Bear of the Day
3 Large-Cap MedTech Growth Stocks to Buy Amid the Pandemic
by Sriparna Ghosal
Let's take a look at three large-cap MedTech stocks that are currently flourishing on the back of a number of positive developments.
Jabil, Harley-Davidson, TMO, LHCG and NovoCure as Zacks Bull and Bear of the Day
by Zacks Equity Research
Jabil, Harley-Davidson, TMO, LHCG and NovoCure as Zacks Bull and Bear of the Day
3 Growth-Focused MedTech Stocks to Buy Amid the COVID-19 Crisis
by Debanjana Dey
Here are three growth stocks from the MedTech space which have maintained stellar performance even during the pandemic-led market meltdown.
Is NovoCure (NVCR) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (NVCR) Outperforming Other Medical Stocks This Year?
NovoCure (NVCR) Q2 Earnings Preview: What's in the Cards?
by Zacks Equity Research
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NovoCure (NVCR) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of -20.00% and -2.19%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
NovoCure (NVCR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medical Services Outlook Bright Amid Coronavirus Crisis
by Urmimala Biswas
Despite the coronavirus-led worldwide sales disruption, medical services is one of the few sectors witnessing industry-wide growth right now.
NovoCure (NVCR) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of 300.00% and 0.11%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Expand Your Portfolio with this First Profit Stock Screener
by Benjamin Rains
We are in the midst of the fourth quarter earnings season. This makes it a great time to use our 'First Profit' stock screener. The idea is to search for companies that recently reported their first quarterly profit...
NovoCure (NVCR) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of 140.00% and 4.82%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will NovoCure (NVCR) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNY
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FNY
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNY
NovoCure Limited (NVCR) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in NovoCure Limited (NVCR).
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of 85.71% and 6.38%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Can NovoCure's (NVCR) Steady Optune Business Aid Q2 Earnings?
by Zacks Equity Research
NovoCure (NVCR) expects to deliver a strong second quarter on solid performance by Optune business.